• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Waters Corporation

    5/23/25 4:30:52 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email
    8-K
    WATERS CORP /DE/ false 0001000697 0001000697 2025-05-22 2025-05-22
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 22, 2025

     

     

    Waters Corporation

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-14010   13-3668640

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    34 Maple Street

    Milford, Massachusetts 01757

    (Address of Principal Executive Offices) (Zip Code)

    (508) 478-2000

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, par value $0.01 per share   WAT  

    New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders

    A total of approximately 55,997,242 shares were present or represented by proxy at the annual meeting of stockholders of Waters Corporation (the “Company”) on May 22, 2025, representing approximately 94.12% of all shares entitled to vote. The final results of voting on each of the matters submitted to a vote of stockholders during the annual meeting are as follows:

    PROPOSAL 1: ELECTION OF DIRECTORS

     

         For    Against    Abstain    Broker
    Non-Votes

    Flemming Ornskov, M.D., M.P.H.

       52,733,323    1,576,324    38,492    1,649,102

    Linda Baddour

       53,254,270    1,055,336    38,533    1,649,102

    Udit Batra, Ph.D.

       54,278,572    36,201    33,366    1,649,102

    Dan Brennan

       53,912,522    397,464    38,153    1,649,102

    Richard Fearon

       52,782,131    1,527,599    38,409    1,649,102

    Pearl. S. Huang, Ph.D.

       53,651,017    633,654    63,468    1,649,102

    Wei Jiang

       53,915,983    394,594    37,562    1,649,102

    Heather Knight

       53,915,084    394,298    38,757    1,649,102

    Christopher A. Kuebler

       49,828,164    3,598,596    921,379    1,649,102

    Mark Vergnano

       53,498,003    810,204    39,932    1,649,102

    In accordance with the Company’s Amended and Restated Bylaws and pursuant to the foregoing vote, each of the nominated directors was re-elected to the Company’s Board of Directors (the “Board”).

    PROPOSAL 2: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

     

    For

     

    Against

     

    Abstain

    51,650,827   3,426,645   919,770

    Pursuant to the foregoing vote, the ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved.

    PROPOSAL 3: NON-BINDING ADVISORY VOTE ON COMPENSATION OF NAMED EXECUTIVE OFFICERS

     

    For

     

    Against

     

    Abstain

     

    Broker
    Non-Votes

    44,725,035   9,559,761   63,344   1,649,102

    Pursuant to the foregoing vote, the stockholders adopted a non-binding, advisory resolution approving the compensation paid to the Company’s named executive officers.

    PROPOSAL 4: APPROVAL OF THE AMENDED AND RESTATED 2009 EMPLOYEE STOCK PURCHASE PLAN

     

    For

     

    Against

     

    Abstain

     

    Broker
    Non-Votes

    54,258,975   28,224   60,940   1,649,102

    Pursuant to the foregoing vote, the stockholders approved the Company’s Amended and Restated 2009 Employee Stock Purchase Plan.


    Signatures

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        WATERS CORPORATION
    Dated: May 23, 2025     By:  

    /s/ Keeley A. Aleman

        Name:   Keeley A. Aleman
        Title:   Senior Vice President, General Counsel and Secretary
    Get the next $WAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    12/10/2025$480.00Peer Perform → Outperform
    Wolfe Research
    12/2/2025$423.00Equal-Weight
    Morgan Stanley
    10/8/2025$390.00Buy
    Rothschild & Co Redburn
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kuebler Christopher A exercised 3,761 shares at a strike of $130.35 and covered exercise/tax liability with 1,318 shares, increasing direct ownership by 16% to 17,478 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    11/7/25 7:00:43 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Knight Heather was granted 78 shares, increasing direct ownership by 11% to 759 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:16:38 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Jiang Wei was granted 73 shares, increasing direct ownership by 3% to 2,551 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    10/2/25 4:15:15 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    SEC Filings

    View All

    SEC Form S-4 filed by Waters Corporation

    S-4 - WATERS CORP /DE/ (0001000697) (Filer)

    12/11/25 9:13:50 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    11/18/25 4:28:10 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 425 filed by Waters Corporation

    425 - WATERS CORP /DE/ (0001000697) (Subject)

    11/10/25 4:16:47 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Waters upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Waters from Peer Perform to Outperform and set a new price target of $480.00

    12/10/25 8:13:37 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Morgan Stanley initiated coverage on Waters with a new price target

    Morgan Stanley initiated coverage of Waters with a rating of Equal-Weight and set a new price target of $423.00

    12/2/25 8:36:30 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rothschild & Co Redburn initiated coverage on Waters with a new price target

    Rothschild & Co Redburn initiated coverage of Waters with a rating of Buy and set a new price target of $390.00

    10/8/25 8:37:34 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Waters Corporation to Present at the Jefferies Global Healthcare Conference in London

    MILFORD, Mass., Nov. 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 18th, 2025, at 2:30 PM Greenwich Mean Time (9:30 AM Eastern Time). A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, m

    11/11/25 2:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Boosts Lab Productivity and Sample Throughput with Launch of its Charged Aerosol Detector Designed for Empower Software

    Drives efficiency and reliability in Quality Control and Development environments, integrating seamlessly with world-class Empower™ Chromatography Data System (CDS).Mitigates CDS communication errors encountered in up to 70% of multi-vendor LC-CAD configurations.1Delivers near-universal detection of an expansive range of analytes across pharmaceutical formulations, food additives, and environmental pollutants, including those that are challenging to measure using UV or mass spectrometry methods.MILFORD, Mass., Nov. 11, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of its Charged Aerosol Detector (CAD) specifically designed for use with Waters Empower Software,

    11/11/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

    Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currencyDelivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidanceInstruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growthRecurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations productsIn constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the AmericasRaising full-year 2025 constant currency sales growth guidance and raisi

    11/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

    4 - WATERS CORP /DE/ (0001000697) (Issuer)

    5/29/24 11:23:35 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Financials

    Live finance-specific insights

    View All

    Waters Corporation (NYSE: WAT) Reports Third Quarter 2025 Financial Results

    Highlights Sales of $800 million exceeded guidance; grew 8% as reported and 8% in constant currencyDelivered GAAP EPS of $2.50 and non-GAAP EPS of $3.40, which reflects strong, 16% growth in Adjusted Earnings Per Share that exceeded guidanceInstruments grew 6% in constant currency, led by high single-digit LC & MS growth, and TA Division returning to positive growthRecurring revenue grew 9% in constant currency; chemistry grew double digits, with strong uptake of new bioseparations productsIn constant currency, Pharma grew 11%, driven by broad-based growth across all regions, including double-digit growth in the AmericasRaising full-year 2025 constant currency sales growth guidance and raisi

    11/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Schedules Third Quarter 2025 Earnings Conference Call

    MILFORD, Mass., Oct. 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q3 2025 financial results conference call on Tuesday, November 4th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least December 2nd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety

    10/1/25 12:00:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation (NYSE: WAT) Reports Second Quarter 2025 Financial Results

    Highlights Sales of $771 million exceeded guidance range; grew 9% as reported and 8% in constant currencyGAAP EPS of $2.47 and non-GAAP EPS of $2.95, above mid-point of guidance range Instruments grew mid-single-digits in constant currency, led by high-single-digit LC and MS growth – with continued strength in instrument replacement, particularly among large pharma and CDMO customersRecurring revenue grew 11% in constant currency, with 9% service growth and double-digit chemistry growthIn constant currency, Pharma grew 11% and Industrial grew 6%, while Academic & Government declined 3%, performing better than expectedRaising full-year 2025 constant currency sales growth guidance to +5.5% to

    8/4/25 6:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    View All

    Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

    MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

    5/21/25 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Heather Knight to Board of Directors

    MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

    8/14/24 4:15:00 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Waters Corporation Appoints Richard Fearon to Board of Directors

    Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

    3/28/23 8:00:00 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Waters Corporation

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    11/12/24 11:54:03 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/14/24 9:37:22 AM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G/A filed by Waters Corporation (Amendment)

    SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

    2/13/24 5:17:31 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials